Citations

Clear

387 citation(s) found for "Couch, Fergus".

Endometriosis in Carriers of a Pathogenic Variant in BRCA1 or BRCA2: A Descriptive Analysis of a Large Multicentral BRCA Carrier Cohort
Mokhber, Aghaghia , Stewart, Bethany , Gronwald, Jacek , Cybulski, Cezary , Kim, Raymond H. , Karlan, Beth Y. , Bordeleau, Louise , Cajal, Teresa Ramón y , Pal, Tuya , Eisen, Andrea , Couch, Fergus J., Zakalik, Dana , Tung, Nadine, Fruscio, Robert , Sun, Ping, Lubiński, Jan , Narod, Steven A. , Stewart, Brynne , Gronwald, Jacek , Cybulski, Cezary , Kim, Raymond H , Karlan, Beth Y , Ramón Y Cajal, Teresa , Pal, Tuya , Eisen, Andrea , Fruscio, Robert , Lubinski, Jan , Narod, Steven A , Bordeleau, Louise , Terry, Kathryn L. , Couch, Fergus J. , Tung, Nadine , Foulkes, William D. , Aeilts, Amber M. , Sun, Ping , Kotsopoulos, Joanne

Mayo Clinic

Current Oncology | December 5, 2025 | Volume: 32 | Issue: 12 | Pages: 675

10.3390/curroncol32120675 | PMID 41440203 Get It

Background: Endometriosis affects an estimated 10% of reproductive-aged women and is associated with increased ovarian cancer risk. While BRCA1/2 mutations are established risk factors for ovarian cancer, their association with endometriosis remains unclear. This study aimed to characterize the prevalence and clinical features of endometriosis within a large cohort of BRCA mutation carriers. Methods: A descriptive analysis was conducted using data from a multi-center longitudinal cohort of women with pathogenic BRCA variants. Reproductive history and related factors were collected through self-reported questionnaires and compared. Results: Among 16,950 BRCA carriers, the prevalence of endometriosis was 2.4%. Compared to BRCA carriers without endometriosis, those with endometriosis were more likely to carry a BRCA2 mutation, have post-secondary education, and experience earlier menarche. BRCA carriers with endometriosis had a lower ovarian cancer prevalence than those without (10% vs. 15%, p < 0.001). Conclusions: This is the first study of this scale to report the prevalence of endometriosis among BRCA mutation carriers, which was lower than previously reported in the general population. The association between endometriosis and ovarian cancer does not appear to be generalizable to this population. Further prospective studies are warranted to clarify this association among BRCA mutation carriers.
Development of a Machine Learning Model for Predicting Treatment-Related Amenorrhea in Young Women with Breast Cancer
Song, Long , Aickelin, Uwe , Khorshidi, Hadi Akbarzadeh , Hamy, Anne‐Sophie , Jayasinghe, Yasmin , Lambertini, Matteo , Condorelli, M. , Pistilli, Barbara , Su, H. Irene , Pang, Patrick Cheong‐Iao , Reyal, Fabien , Sukumvanich, Paniti , Minisini, Alessandro Marco , Ruddy, Kathryn J. , Couch, Fergus J. , Stern, Kate, Agresta, Franca, Chin‐Lenn, Laura , Cui, Wanda, Anazodo, Antoinette , Nguyen, Tuong L. , Partridge, Ann, Macheras‐Magias, Mary, Aickelin, Uwe , Akbarzadeh Khorshidi, Hadi , Hamy, Anne-Sophie , Jayasinghe, Yasmin , Lambertini, Matteo , Su, H Irene , Pang, Patrick Cheong-Iao , Ruddy, Kathryn J , Anazodo, Antoinette , Nguyen, Tuong L , Edib, Zobaida , Hickey, Martha , Anderson, Richard A. , Condorelli, Margherita, Demeestere, Isabelle , Ignatiadis, Michail , Chang, Shanton , Nelson, Scott M. , Puglisi, Fabio , Couch, Fergus J. , Olson, Janet E. , Stafford, Lesley , Gorelik, Alexandra , Saunders, Christobel , Sullivan, Elizabeth , Peate, Michelle

Mayo Clinic

Bioengineering | October 28, 2025 | Volume: 12 | Issue: 11 | Pages: 1171

10.3390/bioengineering12111171 | PMID 41301127 Get It

Treatment-induced ovarian function loss is a significant concern for many young patients with breast cancer. Accurately predicting this risk is crucial for counselling young patients and informing their fertility-related decision-making. However, current risk prediction models for treatment-related ovarian function loss have limitations. To provide a broader representation of patient cohorts and improve feature selection, we combined retrospective data from six datasets within the FoRECAsT (Infertility after Cancer Predictor) databank, including 2679 pre-menopausal women diagnosed with breast cancer. This combined dataset presented notable missingness, prompting us to employ cross imputation using the k-nearest neighbours (KNN) machine learning (ML) algorithm. Employing Lasso regression, we developed an ML model to forecast the risk of treatment-related amenorrhea as a surrogate marker of ovarian function loss at 12 months after starting chemotherapy. Our model identified 20 variables significantly associated with risk of developing amenorrhea. Internal validation resulted in an area under the receiver operating characteristic curve (AUC) of 0.820 (95% CI: 0.817–0.823), while external validation with another dataset demonstrated an AUC of 0.743 (95% CI: 0.666–0.818). A cutoff of 0.20 was chosen to achieve higher sensitivity in validation, as false negatives—patients incorrectly classified as likely to regain menses—could miss timely opportunities for fertility preservation if desired. At this threshold, internal validation yielded sensitivity and precision rates of 91.3% and 61.7%, respectively, while external validation showed 92.9% and 60.0%. Leveraging ML methodologies, we not only devised a model for personalised risk prediction of amenorrhea, demonstrating substantial enhancements over existing models but also showcased a robust framework for maximally harnessing available data sources.
Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer
Ottaviani, Daniela , Ola, Mihaela , Hickey, Seán , Jagušt, Petra , Cosgrove, Nicola , Cocchiglia, Sinéad , Bane, Fiona T., Fallon, Ramón, Daly, Gordon, Hudson, Lance, Kalsi, Shannon, Shovlin, Stephen, Powell, Aoibhín , Bahl, Ash , Ainscow, Ed, Oesterreich, Steffi , Couch, Fergus J. , Hill, Arnold D., Varešlija, Damir , Allotta, Alessandra , Hickey, Seán , Jagust, Petra , Cosgrove, Nicola , Cocchiglia, Sinéad , Bane, Fiona , Fallon, Ramón , Daly, Gordon , Hegarty, Aisling , Hudson, Lance , Sheehan, Katherine , Kalsi, Shannon , Shovlin, Stephen , Powell, Aoibhín , Ainscow, Ed , Oesterreich, Steffi , Lee, Adrian V , Hill, Arnold D K , Varešlija, Damir , Young, Leonie , Chaibi, Yasmine Maati, Lee, Adrian V. , Couch, Fergus J.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 14, 2025 | Volume: 118 | Issue: 3 | Pages: 404-421

10.1093/jnci/djaf295 | PMID 41092317 Get It

Abstract Background Cyclin-dependent kinase 12 (CDK12) regulates general gene transcription elongation and plays multiple roles in RNA splicing, DNA damage-response, cell cycle, and genomic stability. However, transcriptional partners that guide CDK12-specific gene programs have not been identified. Genomic alterations in CDK12 have been observed in multiple cancers, exhibiting both pro-tumorigenic and tumor-suppressive functions, suggesting a context-dependent mechanism of action. Methods CDK12 copy number alterations and gene expression levels were analyzed in matched primary and brain metastatic patient tumors. Clinical significance was assessed by immunohistochemistry in a large cohort of primary breast cancer patient tumors. RNA sequencing, ChIP sequencing, and molecular studies were conducted to explore CDK12’s mechanism of action, and pharmacological studies were performed both in vitro and in vivo using models of advanced (endocrine-resistant and metastatic) estrogen receptor positive (ER+) disease. Results CDK12 amplifications and gene overexpression were observed in brain metastatic tumors. In ER+ primary patient tumors, high CDK12 protein expression was significantly associated with poor overall survival, particularly within the ER+/HER2-negative group. In ER+ endocrine resistant models, CDK12 regulated estrogen signaling pathways, with ER/MED1 identified as the master transcriptional complex directing CDK12-specific pro-tumorigenic gene programs. Pharmacological inhibition of CDK12 significantly reduced viability in endocrine resistant and metastatic cell and organoid models in vitro, and decreased metastatic spread in vivo. Conclusion This work describes a novel mechanism for CDK12, suggesting a potential vulnerability in ER+ breast cancer. These findings provide a basis for further investigation into the role of CDK12 inhibition as a therapeutic approach, particularly in advanced disease settings.
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women
Keil, Alexander P. , Taylor, Jack A. , Yadav, Siddhartha , Culver, Hoda Anton, Auer, Paul L. , Bodelón, Clara , Haiman, Christopher A., Lindströem, Sara, Martinez, Maria Elena, Nathanson, Katherine L. , Patel, Alpa V. , Penney, Kathryn L., Ruddy, Kathryn J. , Teras, Lauren R., Vachon, Celine M. , Weitzel, Jeffrey N. , Yao, Song, Weitzel, Jeffrey N , Yadav, Siddhartha , Taylor, Jack A , Nathanson, Katherine L , O’Brien, Katie M. , Weinberg, Clarice R. , Polley, Eric C. , Boddicker, Nicholas , Hu, Chunling , Ambrosone, Christine B. , Brantley, Kristen D. , Burnside, Elizabeth S. , Chen, Fei , Domchek, Susan M. , Eliassen, A. Heather , Hodge, James M. , Kraft, Peter , Lacey, James V. , Neuhausen, Susan L. , Olson, Janet E. , Palmer, Julie R. , Penney, Kathryn , Scott, Christopher G. , Teras, Lauren R. , Trentham‐Dietz, Amy , Vachon, Celine M. , Yao, Song , Zirpoli, Gary , Couch, Fergus J. , Sandler, Dale P.

Mayo Clinic

JAMA Oncology | October 9, 2025 | Volume: 11 | Issue: 12 | Pages: 1458

10.1001/jamaoncol.2025.3875 | PMID 41066089 Get It

Importance Inherited pathogenic variants (PVs) in known predisposition genes can greatly increase breast cancer risk, but the combined impact of PV status, family history, and other factors on breast cancer risk in the general US population has not been well described. Objective To evaluate population-based breast cancer risk estimates for those with established PVs overall and stratified by first-degree family history of breast cancer and other factors. Design, Setting, and Participants This study used pooled data from 13 US-based breast cancer case-control studies participating in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Enrollment for individual studies occurred between 1976 and 2013, and results are based on data released March 2023, with analyses conducted from June 2022 to July 2025. Exposures PVs, breast cancer family history, self-reported race and ethnicity, and established risk factors. Main Outcomes and Measures Breast cancer rate ratios for PVs in 7 genes were estimated from the CARRIERS consortium. PV status and incidence and mortality statistics were combined using the Individualized Coherent Absolute Risk Estimation (iCARE) model to estimate conditional cumulative breast cancer risks and 95% CIs, stratified by family history and standardized to the US population. Models that incorporated population-based data and published estimates for established epidemiologic risk factors were also evaluated. Results A total of 67 692 women were studied, including 33 841 who were diagnosed with breast cancer. PVs in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 were strongly associated with breast cancer risk, with BRCA1 and PALB2 PVs showing evidence of heterogeneity by family history. In models considering PVs, family history, and established risk factors, the estimated cumulative risks of breast cancer by age 50 years ranged from 2.4% (95% CI, 2.4-2.4) in women with no PVs and no family history to 35.5% (95% CI, 21.6-55.1) in PALB2 PV carriers with a family history. Among women who have not been diagnosed with breast cancer by age 50 years, the cumulative risk of breast cancer by age 80 years ranged from 11.1% (95% CI, 11.0-11.2) in noncarriers with no family history to 70.5% (95% CI, 52.8-83.5) for PALB2 carriers with a family history. PV-specific cumulative risk estimates varied across subgroups defined by race and ethnicity and potentially modifiable epidemiologic risk factors. Conclusions and Relevance In this study, population-based estimates of cumulative breast cancer risk for established PVs, as informed by the CARRIERS case-control sample, varied by family history and potentially modifiable risk factors. These estimates provide guidance for identifying individuals who will most benefit from enhanced screening and prevention strategies.
Factors associated with sleep disturbance in breast cancer survivors over time
Marell, Paulina S. , Vierkant, Robert A. , Larson, Nicole L. , Ehlers, Shawna L. , Donovan, Kristine A. , D’Andre, Stacy D, Couch, Fergus J. , Ruddy, Kathryn J. , D'Andre, Stacy D, Ruddy, Kathryn J , Vierkant, Robert A , Stan, Daniela , Couch, Fergus J. , Olson, Janet E.

Mayo Clinic

The Oncologist | September 20, 2025 | Volume: 30 | Issue: 10 | Pages: No page available

10.1093/oncolo/oyaf297 | PMID 40974175 Get It

Abstract Background Breast cancer (BC) survivors frequently experience sleep disturbances, which may persist for many years after treatment. This study aimed to describe trends in sleep-related symptoms over time and identify factors that may be associated with sleep disturbances in BC survivors. Patients and Methods Adult patients from the Mayo Clinic Breast Disease Registry were surveyed annually for up to 7 years post-diagnosis. Sleep disturbance severity was assessed using numeric rating scales for difficulty falling and staying asleep. Data from 3354 unique patients were analyzed, excluding those with metastatic disease or recurrence. Univariable and multivariable analyses were performed at the 1-year survey timepoint to evaluate disease and patient-related factors that were associated with increased sleep-related symptoms, and these factors were also assessed in relationship to sleep-related symptoms over time. Results In multivariable analyses, more trouble falling asleep was associated with financial insecurity, higher clinical stage, more cigarettes smoked per day, and less weekly exercise. More trouble staying asleep was associated with older age, race, advanced education, financial insecurity, and higher clinical stage. Over time, there was a nonsignificant trend toward increased trouble falling asleep and fluctuations in trouble staying asleep. Higher clinical stage and receipt of radiotherapy were associated with decreased severity in trouble falling asleep over time, while more cigarettes smoked per day was linked to increased severity in trouble staying asleep. Conclusions These findings highlight the complex interplay of clinical, lifestyle, and demographic factors in sleep disturbances among BC survivors, underscoring the need for tailored sleep management strategies.
Abstract A024: A PARP-inhibitor-induced early adaptive survival response is tackled through depletion of FRA1 by brigatinib in high-grade serous ovarian carcinoma
Duffield, Julie R. , Hou, Xiaonan , Wilson, Benjamin, Prasad, Anjali , McKeon-Makki, Iman K. , Huehls, Amelia M. , Wu, Xinyan , Couch, Fergus J., Oberg, Ann L. , Karnitz, Larry M., Correia, Cristina , Larson, Melissa C. , Kaufmann, Scott H. , Kanakkanthara, Arun

Mayo Clinic

Cancer Research | September 19, 2025 | Volume: 85 | Issue: 18_Supplement | Pages: A024-A024

10.1158/1538-7445.ovarian25-a024 Get It

Abstract PARP inhibitors (PARPis) are now a standard of care for high-grade serous ovarian cancer (HGSOC), but resistance to these drugs poses a significant concern, necessitating the exploration of novel treatment strategies. Here we investigated the mechanism underlying enhanced PARPi activity in HGSOC cells following treatment with brigatinib—a second-generation anaplastic lymphoma kinase (ALK) inhibitor approved for treating lung cancer. Our previous work has shown that brigatinib is a dual inhibitor of tyrosine kinases FAK and EPHA2 with subsequent additive reduction in downstream PI3K/AKT and MAPK/ERK cell survival signaling. Suppression of these pathways conferred PARPi sensitivity to HGSOC cell lines and patient-derived xenograft (PDX) models, particularly in those with high FAK and EPHA2. To dissect the mechanism linking the FAK/EPHA2 – AKT/ERK pathway to PARPi synergy, we focused on proteomics approaches which revealed that FRA1—an Activator Protein 1 (AP-1) transcription factor known to be downstream of AKT/ERK—and its targets were decreased by brigatinib treatment. In subsequent phosphoproteomics approaches and cell-based confirmatory studies, a phosphorylation crucial for FRA1 stability was found to be disrupted, leading to reduction in total FRA1 protein levels and synergy with PARPis. To explore how FRA1 mediates response to PARPis, immunoblotting analysis revealed that PARPis increased the abundance of FRA1 in HGSOC cells at early timepoints, indicating potential involvement in an adaptive survival response. Follow-up pharmacologic and gene silencing techniques demonstrated that brigatinib still reduces FRA1 in PARPi-treated cells, and FRA1 depletion induces apoptosis when combined with PARPi to levels comparable to brigatinib treatment. Overall, our studies unveil a beneficial ALK-independent effect of brigatinib that may offer new avenues for considering its repurposing as a HGSOC therapy through disruption of a PARPi-induced adaptive survival mechanism. Citation Format: Julie R. Duffield, Xiaonan Hou, Benjamin W. Wilson, Anjali Prasad, Iman K. McKeon-Makki, Amelia M. Huehls, Xinyan Wu, Cristina Correia, Melissa C. Larson, Fergus J. Couch, Ann L. Oberg, Scott H. Kaufmann, Larry M. Karnitz, Arun Kanakkanthara. A PARP-inhibitor-induced early adaptive survival response is tackled through depletion of FRA1 by brigatinib in high-grade serous ovarian carcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr A024.
A Comparative Study of Quality of Life and Oncologic Outcomes in Premenopausal Women with Hormone Receptor-Positive Breast Cancer: Bilateral Oophorectomy vs. Gonadotropin-Releasing Hormone Agonist Therapy
Erdemoğlu, Evrim , Ruddy, Kathryn J. , Buras, Matthew , Quillen, Jaxon , Larson, Nicole L. , Yi, Johnny , Butler, Kristina , Buras, Matthew R , Larson, Nicole , Butler, Kristina A., Ruddy, Kathryn J , Quillen, Jaxon K , Couch, Fergus J. , Olson, Janet E. , Bozzuto, Laura

Mayo Clinic

Cancers | September 5, 2025 | Volume: 17 | Issue: 17 | Pages: 2916

10.3390/cancers17172916 | PMID 40941013 Get It

Background/Objectives: This study aims to evaluate the quality of life (QoL) and oncological outcomes in premenopausal women diagnosed with hormone receptor-positive breast cancer who are receiving either bilateral oophorectomy (BO) or gonadotropin-releasing hormone agonist (GnRH) therapy. Both methods serve to inhibit ovarian function, which is essential for the management of estrogen-dependent tumors; however, their effects on QoL have yet to be fully clarified. Methods: Data were analyzed from the Mayo Clinic Breast Disease Registry, focusing on women under 55 diagnosed with estrogen receptor-positive breast cancer who received either BO or GnRH within one year of diagnosis. QoL was assessed using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) at baseline and annually for five years. Results: A total of 181 patients were enrolled in the study; 40 into the BO group and 141 to the GnRH group. Both groups exhibited similar levels of sexual dysfunction after a one-year period; however, the BO group stated a higher frequency of hot flashes. PROMIS-10 scores improved in both mental and physical health over time, with no significant differences between the groups. Within the BO group, one recurrence was observed, in contrast to the GnRH group, which had six events. Nonetheless, the difference in recurrence rates did not reach statistical significance. Conclusions: The long-term QoL and oncologic outcomes for premenopausal women with hormone receptor-positive breast cancer were similar for BO and GnRH therapy. These findings emphasize the need for individualized treatment decisions, considering patient preferences and side effects.
Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM
Yadav, Siddhartha , Bao, Riyue , Graham, Rondell P. , Hart, Steven N. , Na, Jie , Boddicker, Nicholas , Gnanaolivu, Rohan , Smadbeck, James , Ding, Li , Billadeau, Daniel D. , Mayer, Aaron T. , Hu, Chunling , Hart, Steven N , Na, Jie , Boddicker, Nicholas J , Gnanaolivu, Rohan , Smadbeck, James B , Ding, Li , Billadeau, Daniel D , Mayer, Aaron T , Majumder, Shounak , Morais Lyra, Paulo Cilas , Lee, Adrian V , Monteiro, Alvaro N , Villasboas, Jose Caetano , McWilliams, Robert R , Couch, Fergus J. , Graham, Rondell P , Yadav, Siddhartha , Hu, Chunling , Majumder, Shounak , Lyra, Paulo C. , Lee, Adrian V. , Monteiro, Álvaro N.A. , Villasboas, José C. , McWilliams, Robert R. , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | August 19, 2025 | Volume: 31 | Issue: 21 | Pages: 4463-4474

10.1158/1078-0432.ccr-24-4120 | PMID 40828413 Get It

Abstract Purpose: Germline pathogenic variants (PV) in ATM increase the risk of pancreatic ductal adenocarcinoma (PDAC), but the underlying tumor biology of PDAC associated with germline PV in ATM has not been adequately explored. Experimental Design: Whole-genome, whole-exome, and RNA sequencing were performed on PDAC tumors from 25 germline ATM PV carriers diagnosed at Mayo Clinic between 2007 and 2017. Somatic and copy-number alterations, mutational signatures, transcriptomic subtypes, and the immune landscape were evaluated. Results: High-quality whole-exome and whole-genome sequencing were obtained from 21 and 15 tumors, respectively. Biallelic inactivation of ATM was observed in 87%, KRAS PV in 90%, CDKN2A homozygous loss in 60%, and TP53 alterations in &lt;10% of these tumors. A predominant clock-like mutational signature was present in all samples. Whole-transcriptome analysis identified that the aberrantly differentiated endocrine exocrine subtype accounted for 18% of PDAC and was consistently associated with &gt;5-year overall survival. In addition, a 28-gene expression–based signature associated with overall survival was identified and further validated in The Cancer Genome Atlas cohort. Immune landscape analysis through CODEX identified enriched CD4 T-helper cell/tumor interactions and reduced B7H3-high cell/tumor interactions in ATM PV carriers compared with noncarriers. Conclusions: The observed absence of TP53 PV and enrichment for CDKN2A alterations in ATM tumors, along with differences in the mutational signatures, transcriptomic subtypes and immune landscape, improve our understanding of the mechanistic pathways involved in PDAC development in germline ATM PV carriers and help identify potential targeted therapeutic strategies.
Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Yadav, Siddhartha , Couch, Fergus J. , Hillman, Sam , Luo, Linlin , Li, Weiyan , Li, Qixin , Hayes, Jennifer Fallas , Xu, Xiaoqing , Couch, Fergus J. , Xu, Xiaoqing , Yadav, Siddhartha , Earla, Jagadeswara Rao

Mayo Clinic

JCO Precision Oncology | July 16, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00814 | PMID 40669020 Get It

PURPOSE Testing for germline BRCA1 and/or BRCA2 mutations (gBRCAm) is recommended for patients with human epidermal growth factor receptor 2–negative (HER2–) breast cancer (BC) to guide treatment selection with poly (ADP-ribose) polymerase inhibitors (PARPis). However, real-world data on germline BRCA1 and/or BRCA2 (gBRCA) testing and PARPi treatment patterns in metastatic BC (mBC) are limited. METHODS Deidentified patient data from adults diagnosed with HER2– mBC between 2014 and 2022 were captured from electronic health records in the US Flatiron Health database. gBRCA testing patterns and prevalence were examined by tumor subtype (hormone receptor–positive [HR+]/triple-negative) and disease stage at diagnosis. Demographic and clinical characteristics were described by receipt of gBRCA testing and PARPi. PARPi treatment patterns were assessed, and real-word overall survival (OS) was estimated in patients with gBRCAm diagnosed with mBC after January 1, 2018. RESULTS Of the 15,006 total patients, 4,654 (31.0%) received a gBRCA test. gBRCA testing rates mostly increased from 2014 to 2022 and were lower in patients with HR+ than triple-negative tumors. Of the patients who underwent gBRCA testing, 337 (7.2%) had gBRCAm. From 2018 to 2022, PARPi was initiated in 94 (45.6%) of 206 patients with gBRCAm. With a median follow-up of 22.8 months across patients with available first-line treatment start dates, real-world OS was numerically longer among 94 patients with gBRCAm who received PARPi (32.3 months [95% CI, 22.7 to 47.4]) than among 99 patients who did not (21.9 months [95% CI, 18.4 to not reached]). CONCLUSION Although gBRCA testing increased over time, testing and PARPi utilization rates remained suboptimal in potentially eligible patients with HER2– mBC. Exploratory analysis showed numerically longer OS in patients who received PARPi. Wider and timelier gBRCA testing is warranted to inform potentially optimal treatment decisions.
Epithelial Abnormalities in the High-Risk Fallopian Tube of a Rare TP53 / BRCA2 Li-Fraumeni Syndrome Patient With Multiple Tumors
Ritting, Megan L. , Warring, Simrit K. , Bettencourt, Manuel M., Aalam, Syed Mohammed Musheer , Shahi, Maryam , Couch, Fergus J. , Couch, Fergus J. , Musheer Aalam, Syed Mohammed , Kannan, Nagarajan , Bakkum‐Gamez, Jamie N. , Kannan, Nagarajan

Mayo Clinic

JCO Precision Oncology | June 24, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00589 | PMID 40554737 Get It